Blueprint Medicines Director Gets $500K Stock Grant, Holds 78K Shares

Blueprint Medicines Corp (BPMC) director Alexis Borisy received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a price of $128.12 per share.

Rhea-AI Filing Summary

Blueprint Medicines Corp (BPMC) director Alexis Borisy received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a price of $128.12 per share. Following this transaction, Borisy directly owns 78,062 shares of the company.

Key details of the RSU grant:

• Vesting occurs at 100% of underlying shares on the earlier of: - June 18, 2026 - Next annual stockholders' meeting
• Each RSU represents a contingent right to receive one share of common stock
• Transaction was reported via Form 4 filing on June 23, 2025

This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership.

Insider Trade Summary

Grant/Award: 3,902 shares

Grant/Award 1 txn

Insider Borisy Alexis

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,902	$128.12	$500K

Holdings After Transaction: Common Stock — 78,062 shares (Direct)

Footnotes (1)

1. F1. The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

FAQ

How many BPMC shares did Alexis Borisy acquire on June 18, 2025?

According to the Form 4 filing, Alexis Borisy acquired 3,902 shares of Blueprint Medicines Corporation (BPMC) in the form of restricted stock units at a price of $128.12 per share.

What is the vesting schedule for BPMC's restricted stock units granted to Alexis Borisy?

The restricted stock units vest 100% on the earlier of (i) June 18, 2026 or (ii) the next annual meeting of Blueprint Medicines Corporation's stockholders. Each RSU represents a right to receive one share of BPMC common stock.

How many BPMC shares does Alexis Borisy own after the June 18, 2025 transaction?

Following the reported transaction, Alexis Borisy directly owns 78,062 shares of Blueprint Medicines Corporation (BPMC) stock.

What is Alexis Borisy's role at BPMC according to the Form 4?

According to the Form 4 filing, Alexis Borisy serves as a Director of Blueprint Medicines Corporation (BPMC), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

When was BPMC's Form 4 filed for Alexis Borisy's stock acquisition?

The Form 4 was filed on June 28, 2025, reporting the transaction that occurred on June 18, 2025. The form was signed by Melissa Masse as Attorney-in-Fact on June 23, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borisy Alexis

(Last) (First) (Middle)

C/O BLUEPRINT MEDICINES CORPORATION

45 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		3,902(1)	A	$128.12	78,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Melissa Masse, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.